These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 33540494)

  • 1. The Clinical Impact of Capmatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification.
    Choi W; Park SY; Lee Y; Lim KY; Park M; Lee GK; Han JY
    Cancer Res Treat; 2021 Oct; 53(4):1024-1032. PubMed ID: 33540494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.
    Wu YL; Smit EF; Bauer TM
    Cancer Treat Rev; 2021 Apr; 95():102173. PubMed ID: 33740553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Capmatinib in
    Wolf J; Seto T; Han JY; Reguart N; Garon EB; Groen HJM; Tan DSW; Hida T; de Jonge M; Orlov SV; Smit EF; Souquet PJ; Vansteenkiste J; Hochmair M; Felip E; Nishio M; Thomas M; Ohashi K; Toyozawa R; Overbeck TR; de Marinis F; Kim TM; Laack E; Robeva A; Le Mouhaer S; Waldron-Lynch M; Sankaran B; Balbin OA; Cui X; Giovannini M; Akimov M; Heist RS;
    N Engl J Med; 2020 Sep; 383(10):944-957. PubMed ID: 32877583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations.
    Kron A; Scheffler M; Wiesweg M; Hummel HD; Kulhavy J; Gatteloehner S; Kollmeier J; Schubart C; Groß T; Demes MC; Keymel S; Joosten M; Merkelbach-Bruse S; Wölwer CB; Tufman A; Kauffmann-Guerrero D; Oeser K; Zehaczek M; Jeratsch U; Wolf J
    Eur J Cancer; 2024 Aug; 207():114158. PubMed ID: 38941869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial.
    Schuler M; Berardi R; Lim WT; de Jonge M; Bauer TM; Azaro A; Gottfried M; Han JY; Lee DH; Wollner M; Hong DS; Vogel A; Delmonte A; Akimov M; Ghebremariam S; Cui X; Nwana N; Giovannini M; Kim TM
    Ann Oncol; 2020 Jun; 31(6):789-797. PubMed ID: 32240796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interstitial lung disease associated with capmatinib therapy in a patient with non-small cell lung cancer harboring a skipping mutation of MET exon 14.
    Kanemura H; Takeda M; Shimizu S; Nakagawa K
    Thorac Cancer; 2021 Feb; 12(4):549-552. PubMed ID: 33347701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.
    Drusbosky LM; Dawar R; Rodriguez E; Ikpeazu CV
    J Hematol Oncol; 2021 Aug; 14(1):129. PubMed ID: 34425853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
    Pruis MA; Geurts-Giele WRR; von der TJH; Meijssen IC; Dinjens WNM; Aerts JGJV; Dingemans AMC; Lolkema MP; Paats MS; Dubbink HJ
    Lung Cancer; 2020 Feb; 140():46-54. PubMed ID: 31862577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non-small cell lung cancer.
    Felip E; Metro G; Tan DSW; Wolf J; Mark M; Boyer M; Hughes BGM; Bearz A; Moro-Sibilot D; Le X; Puente J; Massuti B; Tiedt R; Wang Y; Xu C; Mardjuadi FI; Cobo M
    Lung Cancer; 2024 Jun; 192():107820. PubMed ID: 38763104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capmatinib in Japanese patients with MET exon 14 skipping-mutated or MET-amplified advanced NSCLC: GEOMETRY mono-1 study.
    Seto T; Ohashi K; Sugawara S; Nishio M; Takeda M; Aoe K; Moizumi S; Nomura S; Tajima T; Hida T
    Cancer Sci; 2021 Apr; 112(4):1556-1566. PubMed ID: 33506571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer.
    Saigi M; McLeer-Florin A; Pros E; Nadal E; Brambilla E; Sanchez-Cespedes M
    Clin Transl Oncol; 2018 Jul; 20(7):881-888. PubMed ID: 29139039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation.
    Fujino T; Suda K; Koga T; Hamada A; Ohara S; Chiba M; Shimoji M; Takemoto T; Soh J; Mitsudomi T
    J Hematol Oncol; 2022 Jun; 15(1):79. PubMed ID: 35690785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of Tepotinib Challenge after Capmatinib-Induced Pneumonitis in a Patient with Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation: A Case Report.
    Tseng LW; Chang JW; Wu CE
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Capmatinib in advanced NSCLC for previously treated patients with MET exon 14 skipping mutation].
    Basse C; Régaldo-Saint Blancard L
    Bull Cancer; 2023 Sep; 110(9):869-871. PubMed ID: 37442707
    [No Abstract]   [Full Text] [Related]  

  • 15. FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations.
    Mathieu LN; Larkins E; Akinboro O; Roy P; Amatya AK; Fiero MH; Mishra-Kalyani PS; Helms WS; Myers CE; Skinner AM; Aungst S; Jin R; Zhao H; Xia H; Zirkelbach JF; Bi Y; Li Y; Liu J; Grimstein M; Zhang X; Woods S; Reece K; Abukhdeir AM; Ghosh S; Philip R; Tang S; Goldberg KB; Pazdur R; Beaver JA; Singh H
    Clin Cancer Res; 2022 Jan; 28(2):249-254. PubMed ID: 34344795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of capmatinib in a very elderly patient with metastatic NSCLC harboring a
    Conci N; Marchiori V; Federico AD; Giglio A; Sperandi F; Melotti B; Gelsomino F
    Per Med; 2024; 21(4):205-209. PubMed ID: 38958204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of cross-toxicity between MET inhibitors in a non-small-cell lung cancer with a MET exon 14 skipping mutation.
    Vanderick A; Colinet B
    Acta Clin Belg; 2024 Apr; 79(2):148-151. PubMed ID: 38494868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib.
    Wang SXY; Zhang BM; Wakelee HA; Koontz MZ; Pan M; Diehn M; Kunder CA; Neal JW
    Anticancer Drugs; 2019 Jun; 30(5):537-541. PubMed ID: 30762593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Budget impact of capmatinib for adults with metastatic non-small cell lung cancer harboring a
    Cai B; Zhou ZY; Xue W; Hazra NC; Singh M; Mishra D; Brixner D; Oderda G; Biskupiak J
    J Med Econ; 2021; 24(1):131-139. PubMed ID: 33397178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor.
    Dagogo-Jack I; Moonsamy P; Gainor JF; Lennerz JK; Piotrowska Z; Lin JJ; Lennes IT; Sequist LV; Shaw AT; Goodwin K; Stevens SE; Do A; Digumarthy SR; Price K; Muzikansky A; Hata AN; Heist RS
    J Thorac Oncol; 2021 May; 16(5):850-859. PubMed ID: 33545388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.